BARCELONA, Spain, April 18,
2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE:
GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and
leading manufacturer of plasma-derived medicines that has been
enhancing people's health and well-being for more than 110 years,
today announces the filling of its Annual Report on Form 20-F for
the fiscal year ended December 31,
2022, with the United States Securities and Exchange
Commission ("SEC").
Grifols' annual report under Form 20-F is a critical component
of the company's commitment to transparency and accountability. The
filing of the annual report provides investors with an overview of
the company's governance practices, including information about the
Board of Directors and its committees, executive compensation, and
risk management. This information is critical for stakeholders to
make informed decisions about investing in the company, engaging
with the company on sustainability and governance issues, and
assessing the company's long-term value creation potential.
Grifols' Annual Report on Form 20-F includes, among others, the
financial statements of Grifols for its fiscal year ended
December 31, 2022 in accordance with
International Financial Reporting Standards (IFRS) as adopted by
the International Accounting Standards Board that were audited and
certified in compliance with internal control over financial
reporting by the auditing firm KPMG Auditores, S.L. for the years
2020, 2021 and 2022.
In addition to the financial statements, the annual report also
includes management's discussion and analysis (MD&A) of the
financial condition and results of operations, as well as
information about the company's key performance indicators,
sustainability initiatives. The MD&A provides insights into the
company's performance over the past year, highlighting key drivers
of growth and areas of concern.
Grifols share capital is represented by 426,129,798 ordinary
shares (Class A), with a nominal value of EUR 0.25 per share, and 261,425,110 non-voting
shares (Class B), with a nominal value of EUR 0.05 per share. Grifols ordinary shares
(Class A) are listed on the Spanish stock market and form part of
the IBEX-35 (GRF). Non-voting shares (Class B) are also listed on
the Spanish stock market (GRF.P) and on NASDAQ (GRFS) through ADRs
(American Depositary Receipts).
The 2022 Form 20-F also includes that on April 13, 2023, the Company received a deficiency
letter from the Nasdaq Listing Qualifications Staff of The Nasdaq
Stock Market LLC ("Nasdaq"). The notice was prompted by the
Company's inadvertent falling out of compliance with Nasdaq Listing
Rule 5605(c)(2)(A), which requires that issuers have an audit
committee of at least three members who each meet the criteria for
independence set forth in Rule 10A-3(b)(1) under the Securities
Exchange Act of 1934. The letter does not affect the Company's
listing on Nasdaq or its operations.
The Company fell out of compliance due to the appointment of Mr.
Tomás Dagá to the Company's audit committee, on September 30, 2022. Although Mr. Dagá's
appointment was compliant with the audit committee composition
requirements of the Company's home Spanish regulator, it did not
meet the independence requirements of Nasdaq Listing Rule
5605(c)(2)(A) and Rule 10A-3(b)(1) under the Securities Exchange
Act of 1934 as Mr. Dagá is an external non-independent
director.
As acknowledged by the deficiency letter, the appointment on
April 13, 2023 of Ms. Montserrat
Muñoz to the audit committee to replace Mr. Dagá cured this
deficiency and brought the Company back to compliance.
The Form 20-F can be accessed electronically through the Grifols
website at http://www.grifols.com/en/investors.The Form 20-F is
also available on the SEC's website at http://www.sec.gov.
Grifols will deliver, within a reasonable time after request, a
hard copy of the Form 20-F, including its complete audited
financial statements, free of charge, to any shareholder upon
request. To request a hard copy, shareholders may contact Grifols
by email at investors@grifols.com to the attention of Grifols'
Investor Relations & Sustainability, Re: 2022 Annual Report on
Form 20-F.
About Grifols
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the
health and well-being of people around the world. A leader in
essential plasma-derived medicines and transfusion medicine, the
company develops, produces and provides innovative healthcare
services and solutions in more than 110 countries.
Patient needs and Grifols' ever-growing knowledge of many
chronic, rare and prevalent conditions, at times life-threatening,
drive the company's innovation in both plasma and other
biopharmaceuticals to enhance quality of life. Grifols is focused
on treating conditions across a broad range of therapeutic areas:
immunology, hepatology and intensive care, pulmonology, hematology,
neurology and infectious diseases.
A pioneer in the plasma industry, Grifols continues to grow its
network of donation centers, the world's largest with more than 390
across North America, Europe, Africa and the Middle East and China.
As a recognized leader in transfusion medicine, Grifols offers a
comprehensive portfolio of solutions designed to enhance safety
from donation to transfusion, in addition to clinical diagnostic
technologies. It provides high-quality biological supplies for
life-science research, clinical trials, and for manufacturing
pharmaceutical and diagnostic products. The company also supplies
tools, information and services that enable hospitals, pharmacies
and healthcare professionals to efficiently deliver expert medical
care.
Grifols, with more than 26,000 employees in more than 30
countries and regions, is committed to a sustainable business model
that sets the standard for continuous innovation, quality, safety
and ethical leadership.
In 2022, Grifols' economic impact in its core countries of
operation was EUR 9.6 billion. The
company also generated 193,000 jobs, including indirect and
induced.
The company's class A shares are listed on the Spanish Stock
Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols
non-voting class B shares are listed on the Mercado Continuo
(MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).
For more information, please visit www.grifols.com
View original
content:https://www.prnewswire.com/news-releases/grifols-2022-annual-report-on-form-20-f-filed-with-the-sec-on-april-18-2023-301800274.html
SOURCE Grifols
